安全性和多目标的抗肿瘤活性Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
癌症Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.
癌症Discov. 2017.
PMID:28183697
Free PMC article.
Clinical Trial.